RxDoctor Payments Data

Fadi Alzeidan, MD

Family Medicine · Merrillville, INNPI 1245224724

Payments from drug & device makers

$7,459in general payments, 2019–2025

Across 315 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$795
  • Novo Nordisk$731
  • Johnson & Johnson$375
  • Boston Scientific$364
  • Smith+Nephew$363
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$361
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$7,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,459 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$154,979
Medicare patients
396
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$85,998
EliquisApixaban166$72,166
LinzessLinaclotide51$42,249
XareltoRivaroxaban51$38,872
Tresiba Flextouch U-200Insulin Degludec25$28,436
JanuviaSitagliptin Phosphate28$25,159
EntrestoSacubitril/Valsartan31$16,684
TradjentaLinagliptin43$14,082
FarxigaDapagliflozin Propanediol13$13,206
TrulicityDulaglutide11$10,599
RenvelaSevelamer Carbonate19$9,867
VerquvoVericiguat17$5,728
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro19$5,121
Levemir FlexpenInsulin Detemir13$4,700
Potassium Chloride178$4,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$731$85,99886 claims
PfizerEliquis$138$72,166166 claims
AbbVieLinzess$151$42,24951 claims
Johnson & JohnsonXarelto$375$38,87251 claims
MerckJanuvia, Verquvo$266$30,88745 claims
NovartisEntresto$795$16,68431 claims
Boehringer IngelheimTradjenta$296$14,08243 claims
AstraZenecaFarxiga$296$13,20613 claims
Lilly USA, LLCTrulicity$210$10,59911 claims
Sanofi-aventis U.S. LLCRenvela$35$9,86719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →